White House launches TrumpRx.gov with lower prices listed for Ozempic, Wegovy and Zepbound

On February 5, 2026, the White House launched TrumpRx.gov, a website where patients with valid prescriptions can find discounted prices on 40 branded medicines, including the diabetes and obesity drugs Ozempic, Wegovy and Zepbound ^[1].

Monthly prices for the GLP-1 drugs drop sharply under the announced terms. Ozempic falls from $1,028 to an average of $350, and as low as $199 depending on dosage strength, according to the White House fact sheet ^[1]. Injectable Wegovy falls from $1,349 to the same $350 average, also as low as $199. The Wegovy pill falls from $1,349 to as low as $149. Zepbound, a tirzepatide drug, falls from $1,088 to an average of $346, as low as $299, depending on dosage strength ^[1].

The fact sheet describes Ozempic, Wegovy and Zepbound as products that help adults with diabetes, heart disease (Ozempic and Wegovy only), obesity and other conditions, and says they are the two drugs with the highest annual expenditures in the United States ^[1]. Ozempic and Wegovy are semaglutide; Zepbound is tirzepatide.

The launch features drugs from the first five manufacturers to reach most-favored-nation, or MFN, pricing deals with the administration: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer ^[1]. MFN means paying prices in line with the lowest paid by other developed nations. Drugs from other companies that have signed MFN deals will be added to the site "in the coming months," the fact sheet says ^[1].

Patients reach the savings through coupons they can print or download to a phone, or through manufacturer channels integrated into TrumpRx.gov, depending on the manufacturer ^[1].

The fact sheet also lists discounts on other products, described as examples rather than a full list of the 40: the fertility drug Cetrotide drops from $316 to $22.50, Ovidrel from $251 to $84, and Gonal-F to as low as $168 per pen, with patients who pay for fertility medicines out of pocket saving more than $2,000 per cycle on average; the COPD inhaler Bevespi Aerosphere falls from $458 to $51; the asthma inhaler Airsupra from $504 to $201; the eczema ointment Eucrisa from $792 to $158; insulin lispro as low as $25 a month; and Duavee from $202 to $30 ^[1].

The White House frames the launch as the latest step in an MFN push that began with an executive order on May 12, 2025, followed by letters to manufacturers on July 31, 2025 ^[1]. Since September 30, 2025, the administration says it has announced 16 deals with drugmakers ^[1]. Separately, on December 1, 2025, the Office of the United States Trade Representative, the Department of Commerce and the Department of Health and Human Services announced an agreement with the United Kingdom that will raise the net price of new prescription drugs there by 25 percent ^[1].

The fact sheet does not spell out the full list of 40 medicines, and its examples do not include Mounjaro, Rybelsus or orforglipron (Foundayo).

Why it matters for patients

The listed prices are far below what uninsured patients or cash-paying customers typically face at a pharmacy counter for these drugs. But the fact sheet does not say whether the discounts require paying cash, whether they can be combined with insurance, or whether people covered by Medicare, Medicaid or commercial plans can use them. Whether a patient's copay would be higher or lower than the TrumpRx price has not been disclosed.

It also is not stated how long the prices are guaranteed, or whether the drugs are shipped through the site or filled at a pharmacy. Those details have not been reported. Anyone whose plan currently covers Ozempic, Wegovy or Zepbound would need plan-specific information that the fact sheet does not provide.

What happens next

Additional drugs from companies that have signed MFN deals are to be added to TrumpRx.gov in the coming months; no specific dates were given ^[1].

On January 15, 2026, the president called on Congress to pass "The Great Healthcare Plan," which the fact sheet says would codify the MFN savings, lower insurance premiums and expand price transparency ^[1]. No vote or timeline is described.